Hangzhou Jinlan Pharm-Drugs Technology Co. Ltd.(JL Pharm) is an advanced pharmaceutical corporation with a laboratory of 1200 square meters in Nanjing city, and cooperative GMP production plants in Beljing, Jiangsu, Zhejiang, Jiangxi, Chengdrand Shandong.We can provide both CDMO technology research and development services, and a ful range of laboratory R&D and production services for raw materials and pharmaceutical intermediates to globapharmaceutical companies during which synthetic route research and development, process reearch and development and optimization, scale-up production, domestic and foreign drug registration, and industrial equipment selection, automatic control system and technical process packages.
Packaging & Shipping
Product Description
Product Name: |
Tranexamic Acid |
Synonyms: |
TIMTEC-BB SBB006715;TRANS-4-AMINOMETHYL-1-CYCLOHEXANECARBOXYLIC ACID;trans-4-aminomethylcyclohexane-1-carboxylate;TRANS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID;cyclocapron;cyklokapron;dv-79;emorhalt |
CAS: |
1197-18-8 |
MF: |
C8H15NO2 |
MW: |
157.21 |
EINECS: |
214-818-2 |
Product Categories: |
Pharmaceutical intermediates;API's;4-Substituted Cyclohexanecarboxylic Acids;Amines;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Building Blocks;C8;API;CYKLOKAPRON;Cosmetics;Hemostatic;Pharmaceutical raw materials;Carbonyl Compounds;Carboxylic Acids;Chemical Synthesis;Organic Building Blocks;1197-18-8 |
Mol File: |
1197-18-8.mol |
Tranexamic Acid Chemical Properties |
Installation Instructions
Hazard Codes |
Xi |
Risk Statements |
36/37/38 |
Safety Statements |
26-36-37/39 |
WGK Germany |
2 |
RTECS |
GU8400000 |
HazardClass |
IRRITANT |
HS Code |
29224999 |
Toxicity |
LD50 in mice, rats (mg/kg): 1500, 1200 i.v. (Melander) |
Uses |
Fibrinolysis, the cleavage of fibrin by plasmin, is a normal step in the dissolution of fibrin clots after wound repair. Tranexamic acid is an inhibitor of fibrinolysis that blocks the interaction of plasmin with fibrin (IC50 = 3.1 μM). It is a lysine mimetic that binds the lysine binding site in plasmin. Antifibrinolytic agents have value when fibrinolytic activity is abnormally high or when coagulation is impaired. |